---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-22-012871"
form_type: "8-K"
ticker: "OMER"
cik: "0001285819"
company_name: "OMEROS CORP"
filed_at: "2022-08-09T23:59:59+00:00"
generated_at: "2026-06-24T01:49:56.278594+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Omeros reports Q2 2022 net loss $30.9M; narsoplimab FDA dispute decision expected August

## Summary
- Royalties of $17.2M on OMIDRIA sales of $34.5M, a new all-time high.
- Net loss $30.9M ($0.49/share) vs $28.6M ($0.46/share) in Q2 2021.
- Cash and short-term investments $122.6M as of June 30, down $19.7M from Q1.
- Submitted Formal Dispute Resolution to FDA for narsoplimab in TA-TMA; decision expected in August 2022.
- OMS906 received orphan drug designation for PNH; Phase 1b trials expanding to treatment-naïve and C3G patients.

## SEC filing metadata
- accession: 0001558370-22-012871
- form_type: 8-K
- ticker: OMER
- cik: 0001285819
- company_name: OMEROS CORP
- filed_at: 2022-08-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1285819/000155837022012871/0001558370-22-012871-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1285819/000155837022012871/omer-20220809x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-22-012871
- JSON: https://secwatch.observer/filing/0001558370-22-012871.json
- Plain text: https://secwatch.observer/filing/0001558370-22-012871.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.